ERBB2 and breast cancer: This molecular sub-classification has served as a guiding principle for the utility of targeted therapies such as synthetic lethality using poly ADP ribose polymerase (PARP) inhibitors HER2-targeted (e.g., Trastuzumab) and hormonal (e.g., Tamoxifen) therapies, leading to better outcomes and management of BC [5].